Walleye Capital’s ADC Therapeutics ADCT Stock Holding History

Walleye Capital’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$290K	Buy	+77,390	New	+$305K	﹤0.01%	3086
2025 Q4	–	Sell	-177,032	Closed	-$708K	–	4495
2025 Q3	$708K	Buy	+177,032	New	+$558K	﹤0.01%	2347
2023 Q1	–	Sell	-513,618	Closed	-$1.97M	–	3873
2022 Q4	$1.97M	Sell	513,618 -182,645	-26%	-$730K	0.04%	588
2022 Q3	$3.36M	Sell	696,263 -192,437	-22%	-$1.39M	0.06%	328
2022 Q2	$7.07M	Buy	888,700 +640,346	+258%	+$6.06M	0.19%	111
2022 Q1	$3.65M	Buy	248,354 +202,876	+446%	+$3.22M	0.1%	221
2021 Q4	$919K	Buy	+45,478	New	+$1.1M	0.03%	642

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Walleye Capital's ADCT Position: Q1 2026 in Review

Walleye Capital opened a new position in ADC Therapeutics (ADCT) in Q1 2026: 77,390 shares worth $290K. The stake represents ﹤0.01% of the portfolio and ranks #3086 among its holdings. This is a return to the name: Walleye Capital previously reported a position in ADCT as recently as Q3 2025.

Walleye Capital first reported a position in ADCT in Q4 2021 and has held it in 7 quarters since. The position peaked at $7.07M in Q2 2022. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

Walleye Capital held 77,390 shares of ADC Therapeutics worth $290K as of Q1 2026.
ADC Therapeutics was a new Walleye Capital position in Q1 2026.
ADC Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #3086 holding.
Walleye Capital first reported a position in ADC Therapeutics in Q4 2021 and has held it in 7 quarters since.
Walleye Capital's ADC Therapeutics position peaked at $7.07M in Q2 2022.
118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.